Companies in #Schizophrenia

Digital therapeutics company developing prescription software treatments for neuropsychiatric and neurological conditions, including schizophrenia, major depressive disorder and migraine.

Karuna Therapeutics is a clinical-stage biopharmaceutical company developing novel therapies for neuropsychiatric disorders, with a focus on muscarinic receptor-targeted treatments.

Lundbeck is a Danish specialty pharmaceutical company focused on central nervous system (CNS) disorders including depression, schizophrenia, Parkinson's disease, and migraine. Vyepti (eptinezumab), its CGRP-targeting migraine therapy, is a key growth asset.

Clinical-stage neuroscience company developing small-molecule therapies for autism spectrum disorder, schizophrenia, and other CNS conditions.

Neumora Therapeutics is a clinical-stage neuroscience company developing precision medicines for brain diseases with high unmet need. Its lead asset NMRA-140 (navacaprant) is a kappa opioid receptor antagonist studied in major depressive disorder, and the company has additional programs in schizophrenia and other CNS indications. Following two Phase 3 failures in mid-2026, Neumora announced a 35% workforce reduction and is discontinuing development of its lead depression asset.

Neumora Therapeutics is a clinical-stage neuroscience company in Watertown, Massachusetts, developing small-molecule medicines for brain diseases with high unmet need. Its lead programme navacaprant (NMRA-140), a kappa opioid receptor antagonist, was discontinued in June 2026 after the Phase 3 KOASTAL-2 and KOASTAL-3 trials in major depressive disorder failed to reach statistical significance on primary and key secondary endpoints, a decision accompanied by a workforce reduction of roughly 35%. The company has since re-based its pipeline on three earlier assets: NMRA-511, a vasopressin 1a receptor antagonist in Alzheimer's disease agitation that has reported a Phase 1b clinical signal and is moving into higher-dose and Phase 2 work; NMRA-898, an M4 positive allosteric modulator in schizophrenia; and NMRA-215, an NLRP3 inhibitor for obesity and cardiometabolic disease. Neumora held $116.8 million in cash and equivalents at June 30, 2026, guided to fund operations into the third quarter of 2027, and in October 2026 received a Nasdaq notice that its share price had traded below the $1.00 minimum bid for 30 consecutive business days, with until April 26, 2027 to regain compliance and a reverse stock split under consideration.

Bresso, Italy-based CNS biopharmaceutical company developing evenamide, a glutamate modulator in Phase 3 for treatment-resistant schizophrenia, and marketing Xadago (safinamide) for Parkinson's disease.

Pasithea Therapeutics is a clinical-stage biotechnology company developing small-molecule and antibody therapies for RASopathies, MAPK pathway-driven tumours and central nervous system disorders. Its lead candidate, PAS-004, is a next-generation macrocyclic MEK inhibitor designed for chronic dosing with a long half-life and partial pathway inhibition intended to widen the therapeutic window relative to earlier MEK inhibitors; it is in a Phase 1b dose-escalation study in adults with neurofibromatosis type 1, with cutaneous neurofibromas as the primary development focus and additional potential in BRAF-driven tumours and ETS2-driven inflammatory disease. The company is also developing PAS-003 for amyotrophic lateral sclerosis and PAS-001 for schizophrenia. Pasithea was founded in 2020 by Dr. Lawrence Steinman and listed on Nasdaq in September 2021; it is headquartered in Miami Beach, Florida and operates with a small team of five employees.